Trial Profile
MK0767 in Type 2 Diabetes (0767-012)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0767 (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 02 Mar 2014 New trial record